Orthofix Medical Inc. (OFIX) Stock Price & Analysis
Orthofix Medical Inc. (OFIX) rose 2.65% to USD 11.25 as of July 25, 2026 at 04:14 UTC, according to Nexqual real-time market data.
OFIX last closed at USD 10.96; the session ranged USD 10.95–11.38 on volume of 226,011 shares. Market capitalization is $454.74M, with a 52-week range of USD 8.85–16.99 (NMS). Source: Nexqual, July 25, 2026 at 04:14 UTC.
Key Statistics (as of July 25, 2026 at 04:14 UTC)
| Price | USD 11.25 |
|---|---|
| Change | ▲ 2.65% (up) |
| Previous Close | USD 10.96 |
| Open | USD 10.95 |
| Day Range | USD 10.95 – 11.38 |
| 52-Week Range | USD 8.85 – 16.99 |
| Volume | 226,011 shares |
| Market Cap | $454.74M |
| Exchange | NMS |
Technical Analysis (OFIX)
Nexqual's technical model rates OFIX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 04:14 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.39 (neutral) |
| vs SMA50 | Above (USD 10.46) |
| MACD | 0.31 (positive) |
Analyst Ratings (OFIX)
Wall Street analysts rate OFIX "Buy" based on 4 analysts, with a mean price target of USD 15.5 (range USD 12–18), per Nexqual as of July 25, 2026 at 04:14 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 15.5 |
| High Target | USD 18 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (OFIX)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.03 |
| Revenue Estimate | $209.28M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.11 vs est -0.29 ▲ beat |
| 2025-12-31 | USD 0.24 vs est 0.42 ▼ miss |
| 2025-09-30 | USD 0.2 vs est 0.12 ▲ beat |
| 2025-06-30 | USD 0.13 vs est 0.04 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:14 UTC.
Financials & Fundamentals (OFIX)
| Total Revenue | $825.37M |
|---|---|
| Revenue Growth (YoY) | +1.60% |
| Gross Margin | +71.01% |
| Operating Margin | -6.75% |
| Profit Margin | -7.27% |
| ROE | -13.43% |
| Debt / Equity | 60.26 |
| Current Ratio | 2.87 |
| Total Cash | $120.28M |
| Total Debt | $262.26M |
| Free Cash Flow | $22.02M |
Source: Nexqual, July 25, 2026 at 04:14 UTC.
Financial Health Score (OFIX)
Nexqual rates Orthofix Medical Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:14 UTC.
| Growth | Mixed — Revenue +2.9% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 71%, operating -7% |
| Balance Sheet | Strong — $120M cash vs $262M debt |
| Cash Flow | Mixed — FCF $22M, slim 2.7% margin |
| Efficiency | Critical — ROE -13%, ROA -3.3% |
Ownership (OFIX)
| Insider Ownership | +2.19% |
|---|---|
| Institutional Ownership | +91.96% |
| Shares Outstanding | 40.42M |
| Float | 40.10M |
| Short % of Float | +6.61% |
Source: Nexqual, July 25, 2026 at 04:14 UTC.
Leadership (OFIX)
Orthofix Medical Inc. is led by Massimo Calafiore (age 53), President, CEO & Director, per Nexqual as of July 25, 2026 at 04:14 UTC.
| President, CEO & Director | Massimo Calafiore (age 53) |
|---|---|
| Chief Financial Officer | Julie B. Andrews (age 54) |
| President of Global Operations & Quality | Aviva McPherron (age 48) |
| President of Global Biologics & Limb Reconstruction | Patrick Fisher (age 51) |
Major Backers & Investors (OFIX)
Notable institutional backers of Orthofix Medical Inc. include Engine Capital Management, LP, Juniper Investment Company, LLC, Rubric Capital Management LP, according to Nexqual as of July 25, 2026 at 04:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Engine Capital Management, LP | 10.86% |
| Juniper Investment Company, LLC | 9.84% |
| Rubric Capital Management LP | 9.21% |
| Paradigm Capital Management | 8.18% |
| Armistice Capital, LLC | 6.68% |
| Millennium Management | 2.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.07% |
| Vanguard Group | 8.59% |
| Geode Capital | 2.32% |
| State Street | 2.24% |
Source: Nexqual, July 25, 2026 at 04:14 UTC.
From Orthofix Medical Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally.
- It operates through two segments, Global Spine and Global Limb Reconstruction.
- This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures.
- The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNMD | CONMED Corporation | USD 42.68 | ▲ 1.62% |
| MMSI | Merit Medical Systems, Inc. | USD 74.32 | ▲ 1.66% |
| ICUI | ICU Medical, Inc. | USD 157.44 | ▲ 0% |
| IART | Integra LifeSciences Holdings C | USD 19.79 | ▲ 5.15% |
| ATRC | AtriCure, Inc. | USD 35.04 | ▲ 4.53% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:14 UTC. This page is informational and not investment advice.